Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Tasimelteon

EU orphan designation number: EU/3/10/841   
Active ingredient: Tasimelteon
Indication: Treatment of non-24-hour sleep-wake disorders in blind people with no light perception
Sponsor: Vanda Pharmaceuticals Limited
222 Regent Street, London W1B 5TR, United Kingdom
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Hetlioz on 07/07/2015 with the number EU/1/15/1008

   Public summary of scientific opinion     EPAR

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
01/03/2011 Orphan designation EMA/OD/102/10 (2011)1307 of 23/02/2011
24/11/2014 Change of name and/or address of sponsor